Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 16, Issue 4, 2004, Pages 485-500

  Loughlin, A ^a,b   Metsch, L ^b   Gardner, L ^c   Anderson Mahoney, P ^d   Barrigan, M ^e   Strathdee, S ^f  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d Health Research Association   (United States)

^e EMORY UNIVERSITY   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ALCOHOLISM; CONSULTATION; DISEASE ASSOCIATION; DRUG ABUSE; DRUG DEPENDENCE; DRUG UTILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MENTAL DISEASE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EMPIRICAL APPROACH; HEALTH CARE AND PUBLIC HEALTH;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATTITUDE OF HEALTH PERSONNEL; HIV INFECTIONS; HUMANS; ODDS RATIO; PHYSICIAN'S PRACTICE PATTERNS; REFUSAL TO TREAT; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS;

EID: 2442486434     PISSN: 09540121     EISSN: None     Source Type: Journal    
DOI: 10.1080/09540120410001683411     Document Type: Review

References (63)

1. ALTICE, F.L., MOSTASHARI, F. & FRIEDLAND, G.H. (2001). Trust and the acceptance of and adherence to antiretroviral therapy. Journal of Acquired Immune Deficiency Syndrome, 28, 47-58.
2. ANDERSEN, R, BOZZETTE, S., SHAPIRO, M., ST CLAIR, P., MORTON, S., CRYSTAL, S., GOLDMAN, D., WENGER, N., GIFFORD, A., LEIBOWITZ, A., ASCH, S., BERRY, S., NAKAZONO, T., HESLIN, K. & CUNNINGHAM, W. (2000). Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Services Research, 35, 389-416.
3. ANDERSON, K.H. & MITCHELL, J.M. (2000). Differential access in the receipt of antiretroviral drugs for the treatment of AIDS and its implications for survival. Archive of Internal Medicine, 160, 3114-3120.
4. ANGELINO, A.F. & TREISMAN, G.J. (2001). Management of psychiatric disorders in patients infected with human immunodeficiency virus. Clinical Infectious Diseases, 33, 847-856.
5. ANTELA, A. (2001). Access to antiretroviral therapy in HIV-infected injection drug users. AIDS, 15, 1727-1728.
6. BAMBERGER, J.D., UNICK, J., KLEIN, P., FRASER, M., CHESNEY, M. & KATZ, M.H. (2000). Helping the urban poor stay with antiretroviral HIV drug therapy. American Journal of Public Health, 90, 699-701.
7. BANGSBERG, D.R. & MOSS, A. (1999). When should we delay highly active antiretroviral therapy? Journal of General Internal Medicine, 14, 446-448.
8. BANGSBERG, D.R., MUNDY, L.M. & TULSKY, J.P. (2001). Expanding directly observed therapy: tuberculosis to human immunodeficiency virus. American Journal of Medicine, 110, 664-666.
9. BANGSBERG, D.R., TULSKY, J.P., HECHT, F.M. & MOSS, A.R. (1997). Protease inhibitors in the homeless. Journal of the American Medical Association, 278, 63-65.
10. BASSETTI, S., BATTEGAY, M., FURRER, H., RICKENBACH, M., FLEPP, M., KAISER, L., TELENTI, A., VERNAZZA, P.L., BERNASCONI, E. & SUDRE, P. (1999). Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndrome, 21, 114-119.
11. BING, E.G., BURNAM, M.A., LONGSHORE, D., FLEISHMAN, J.A., SHERBOURNE, C.D., LONDON, A.S., TURNER, B.J., EGGAN, F., BECKMAN, R, VITIELLO, B., MORTON, S.C., ORLANDO, M., BOZZETTE, S.A., ORTIZ-BARRON, L. & SHAPIRO, M. (2001). Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Archive of General Psychiatry, 58, 721-728.
12. BURNAM, M.A., BING, E.G., MORTON, S.C., SHERBOURNE, C., FLEISHMAN, J.A., LONDON, A.S., VITIELLO, B., STEIN, M., BOZZETTE, S.A. & SHAPIRO, M.F. (2001). Use of mental health and substance abuse treatment services among adults with HIV in the United States. Archive of General Psychiatry, 58, 729-736.
13. CELENTANO, D.D., GALAI, N., SETHI, A.K., SHAH, N.G., STRATHDEE, S.A., VLAHOV, D. & GALLANT, J.E. (2001). Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS, 15, 1707-1715.
14. CELENTANO, D.D., VLAHOV, D., COHN, S., SHADLE, V.M., OBASANJO, O. & MOORE, R D. (1998). Self-reported antiretroviral therapy in injection drug users. Journal of the American Medical Association, 280, 544-546.
15. CENTERS FOR DISEASE CONTROL (2001). HIV prevention strategic plan through 2005. Atlanta, GA: CDC.
16. CENTERS FOR DISEASE CONTROL (2002). HIV/AIDS surveillance report through June 2001, 13(1). Atlanta, GA: CDC.
17. CHAISSON, R.E., KERULY, J.C. & MOORE, R.D. (1995). Race, sex, drug use, and progression of human immunodeficiency virus disease. New England Journal of Medicine, 333, 751-756.
18. CLARKE, S.M. & MULCAHY, F.M. (2000). Antiretroviral therapy for drug users. International Journal of STD and AIDS, 11, 627-631.
19. COOK, J.A., COHEN, M.H., GREY, D., KIRSTETN, L., BURKE, J., ANASTOS, K., PALACIO, H., RICHARDSON, J., WILSON, T.E. & YOUNG, M. (2002). Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. American Journal of Public Health, 92, 82-87.
20. CRYSTAL, S., SAMBAMOORTHI, U., MOYNIHAN, P.J. & MCSPIRITT, E. (2001). Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS. Journal of General Internal Medicine, 16, 850-859.
21. CUNNINGHAM, W.E., ANDERSEN, R.M., KATZ, M.H., STEIN, M.D., TURNER, B.J., CRYSTAL, S., ZIERLER, S., KUROMIYA, K., MORTON, S.C., ST CLAIR, P., BOZZETTE, S.A. & SHAPIRO, M.F. (1999). The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States. Medical Care, 37, 1270-1281.
22. DHHS (2002). Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. Morbidity and Mortality Weekly Report, 51, 1-55.
23. DIGGLE, P.J., LIANGE K. & ZEGER S. (1994). Analysis of longitudinal data. Oxford: Clarendon Press.
24. FAIRFIELD, K.M., LIBMAN, H., DAVIS, R.B. & EISENBERG, D.M. (1999). Delays in protease inhibitor use in clinical practice. Journal of General Internal Medicine, 14, 395-401.
25. FERRANDO, S.J., WALL, T.L., BATKI, S.L. & SORENSEN, J.L. (1996). Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. American Journal of Drug and Alcohol Abuse, 22, 475-487.
26. GANGE, S.J., BARRON, Y., GREENBLATT, R.M., ANASTOS, K., MINKOFF, H., YOUNG, M., KOVACS, A., COHEN, M., MEYER, W.A., III & MUNOZ, A. (2002). Effectiveness of highly active antiretroviral therapy among HIV-1 infected women. Journal of Epidemiology and Community Health, 56, 153-159.
27. GARDNER, L.I., HOLMBERG, S.D., MOORE, J., ARNSTEN, J.H., MAYER, K.H., ROMPALO, A., SCHUMAN, P. & SMITH, D.K. (2002). Use of highly active antiretroviral therapy in HIV-infected women: impact of HIV specialist care. Journal of Acquired Immune Deficiency Syndrome, 29, 69-75.
28. GERBERT, B., BRONSTONE, A., CLANON, K., ABERCROMBIE, P. & BANGSBERG, D. (2000). Combination antiretroviral therapy: health care providers confront emerging dilemmas. AIDS Care, 12, 409-421.
29. GORDIS L. (1996). Epidemiology. Philadelphia: W.B. Saunders.
30. HADER, S.L., SMITH, D.K., MOORE, J.S. & HOLMBERG, S.D. (2001). HIV infection in women in the United States: status at the Millennium. Journal of the American Medical Association, 285, 1186-1192.
31. RESEARCH NETWORK, HIV (2002). Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. Journal of Acquired Immune Deficiency Syndrome, 30, 21-26.
32. HSU, L.C., VITTINGHOFF, E., KATZ, M.H. & SCHWARCZ, S.K. (2001). Predictors of use of highly active antiretroviral therapy (HAART) among persons with AIDS in San Francisco, 1996-1999. Journal of Acquired Immune Deficiency Syndrome, 28, 345-350.
33. KARON, J.M., FLEMING, P.L., STEKETEE, R.W. & DE COCK, K.M. (2001). HIV in the United States at the turn of the century: an epidemic in transition. American Journal of Public Health, 91, 1060-1068.
34. KATZ, M.H., CUNNINGHAM, W.E., FLEISHMAN, J.A., ANDERSEN, R.M., KELLOGG, T., BOZZETTE, S.A. & SHAPIRO, M.F. (2001). Effect of case management on unmet needs and utilization of medical care and medications among HIV-infected persons. Annals of Internal Medicine, 135, 557-565.
35. KATZ, M.H., CUNNINGHAM, W.E., MOR, V., ANDERSEN, R.M., KELLOGG, T., ZIERLER, S., CRYSTAL, S.C., STEIN, M.D., CYLAR, K., BOZZETTE, S.A. & SHAPIRO, M.F. (2000). Prevalence and predictors of unmet need for supportive services among HIV-infected persons: impact of case management. Medical Care, 38, 58-69.
36. KERULY, J.C., CONVISER, R. & MOORE, R.D. (2002). Association of medical insurance and other factors with receipt of antiretroviral therapy. American Journal of Public Health, 92, 852-857.
37. KILBOURNE, A.M., JUSTICE, A.C., RABENECK, L., RODRIGUEZ-BARRADAS, M. & WEISSMAN, S. (2001). General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era. Journal Clinical Epidemiology, 54 (Suppl. 1), S22-S28.
38. KITAHATA, M.M., KOEPSELL, T.D., DEYO, R.A., MAXWELL, C.L., DODGE, W.T. & WAGNER, E.H. (1996). Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. New England Journal of Medicine, 334, 701-706.
39. KNOWLTON, A.R., HOOVER, D.R., CHUNG, S.E., CELENTANO, D.D., VLAHOV, D. & LATKIN, C.A. (2001). Access to medical care and service utilization among injection drug users with HIV/AIDS. Drug and Alcohol Dependance, 64, 55-62.
40. LAINE, C., HAUCK, W.W., GOUREVITCH, M.N., ROTHMAN, J., COHEN, A. & TURNER, B.J. (2001). Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs. Journal of the American Medical Association, 285, 2355-2362.
41. LUCAS, G.M., CHEEVER, L.W., CHAISSON, R.E. & MOORE, R.D. (2001). Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. Journal of Acquired Immune Deficiency Syndrome, 27, 251-259.
42. MANNHEIMER, S.B., CURTIS, J.L. & EL SADR, W.M. (1999). Use of antiretroviral therapy by intravenous drug users with HIV. Journal of the American Medical Association, 281, 699-691.
43. MAUSNER, J.S. & KRAMER, S. (1985). Mausner & Bahn Epidemiology: an introductory text. Philadelphia: W.B. Saunders.
44. MICHAELS, S.H., CLARK, R. & KISSINGER, P. (1999). Use of antiretroviral therapy by intravenous drug users with HIV. Journal of the American Medical Association, 281, 699-700.
45. MITTY, J.A., MCKENZIE, M., STENZEL, M., FLANIGAN, T. & CARPENTER, C. C. (1999). Modified directly observed therapy for treatment of human immunodeficiency virus. Journal of the American Medical Association, 282, 1334.
46. MITTY, J.A., STONE, V.E., SANDS, M., MACALINO, G. & FLANIGAN, T. (2002). Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clinical Infectious Diseases, 34, 984-990.
47. MOATTI, J.P., CARRIERI, M.P., SPIRE, B., GASTAUT, J.A., CASSUTO, J.P. & MOREAU, J. (2000). Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS, 14, 151-155.
48. MURRI, R, AMMASSARI, A., DE LUCA, A., CINGOLANI, A., ANTINORI, A. & ORTONA, L. (1999). Use of antiretroviral therapy by intravenous drug users with HIV. Journal of the American Medical Association, 281, 700-701.
49. O'CONNOR, P.G., SELWYN, P.A. & SCHOTTENFELD, R.S. (1994). Medical care for injection-drug users with human immunodeficiency virus infection. New England Journal of Medicine, 331, 450-459.
50. PAUL, S., GILBERT, H. M., LANDE, L., VAAMONDE, C. M., JACOBS, J., MALAK, S. & SEPKOWITZ, K. A. (2002). Impact of Antiretroviral Therapy on Decreasing Hospitalization Rates of HIV-infected Patients in 2001. AIDS Research and Human Retroviruses, 18, 501-506.
51. ROMPALO, A., SHAN, N., MARGOLIC, J., FARZADEGAN, H., ARNSTEN, J., SHUMAN, P., RICH, J, GARDNER, L., SMITH, D. & VLAHOV, D. (in press). Evaluation of possible effects of continued drug use on HIV progression among women. International Journal of STIs and AIDS.
52. SAMBAMOORTHI, U., WARNER, L.A., CRYSTAL, S. & WALKUP, J. (2000). Drug abuse, methadone treatment, and health services use among injection drug users with AIDS. Drug and Alcohol Dependence, 60, 77-89.
53. SAMET, J.H., FREEDBERG, K.A., STEIN, M.D., LEWIS, R., SAVETSKY, J., SULLIVAN, L., LEVENSON, S.M. & HINGSON, R. (1998). Trillion virion delay: time from testing positive for HIV to presentation for primary care. Archives of Internal Medicine, 158, 734-740.
54. SHAPIRO, M.F., MORTON, S.C., MCCAFFREY, D.F., SENTERFITT, J.W., FLEISHMAN, J.A., PERLMAN, J.F., ATHEY, L.A., KEESEY, J.W., GOLDMAN, D.P., BERRY, S.H. & BOZZETTE, S.A. (1999). Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. Journal of the American Medical Association, 281, 2305-2315.
55. SHERER, R. (1998). Adherence and antiretroviral therapy in injection drug users. Journal of the American Medical Association, 280, 567-568.
56. SOLLITTO, S., MEHLMAN, M., YOUNGNER, S. & LEDERMAN, M.M. (2001). Should physicians withhold highly active antiretroviral therapies from HIV-AIDS patients who are thought to be poorly adherent to treatment? AIDS, 15, 153-159.
57. STEINBROOK, R. (2001). Providing antiretroviral therapy for HIV infection. New England Journal of Medicine, 344, 844-846.
58. STENZEL, M.S., MCKENZIE, M., MITTY, J.A. & FLANIGAN, T.P. (2001). Enhancing adherence to HAART: a pilot program of modified directly observed therapy. AIDS Reader, 11, 317-318.
59. STRATHDEE, S.A., PALEPU, A., CORNELISSE, P.G., YIP, B., O'SHAUGHNESSY, M.V., MONTANER, J.S., SCHECHTER, M.T. & HOGG, R.S. (1998). Barriers to use of free antiretroviral therapy in injection drug users. Journal of the American Medical Association, 280, 547-549.
60. TURNER, B.J., CUNNINGHAM, W.E., DUAN, N., ANDERSEN, R.M., SHAPIRO, M.F., BOZZETTE, S.A., NAKAZONO, T., MORTON, S., CRYSTAL, S., ST CLAIR, P., STEIN, M. & ZIERLER, S. (2000). Delayed medical care after diagnosis in a US national probability sample of persons infected with human immunodeficiency virus. Archives of Internal Medicine, 160, 2614-2622.
61. TURNER, B.J., FLEISHMAN, J.A., WENGER, N., LONDON, A.S., BURNAM, M.A., SHAPIRO, M.F., BING, E.G., STEIN, M.D., LONGSHORE, D. & BOZZETTE, S.A. (2001a). Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. Journal of General Internal Medicine, 16, 625-633.
62. TURNER, B.J., ZHANG, D., LAINE, C., POMERANTZ, R.J., COSLER, L. & HAUCK, W.W. (2001b). Association of provider and patient characteristics with HIV-infected women's antiretroviral therapy regimen. Journal of Acquired Immune Deficiency Syndrome, 27, 20-29.
63. TYNDALL, M.W, CRAIB, K.J., CURRIE, S., LI, K., O'SHAUGHNESSY, M.V. & SCHECHTER, M.T. (2001). Impact of HIV infection on mortality in a cohort of injection drug users. Journal of Acquired Immune Deficiency Syndrome, 28, 351-357.